Gretchen Zimmermann, MBA, RD, VP of Clinical Strategy at Vida Health
The false belief that people with obesity do not have eating disorders is one of the most harmful misconceptions in obesity care. In reality,…
Continue Reading
Patent Monopolies Drive Record Profits
Novo Nordisk and Eli Lilly have transformed GLP-1 receptor agonists into unprecedented profit machines. These blockbuster drugs, approved for diabetes and weight loss, generate billions while leaving many patients unable…
What You Should Know:
– Veradigm, a provider of healthcare data and technology solutions, today announced a significant advancement in the application of artificial intelligence (AI) to scale the generation of real-world evidence (RWE) for…
Continue Reading
Indianapolis-based pharmaceutical behemoth Eli Lilly has filed lawsuits against four compounders claiming that they sold unapproved products that contain tirzepatide, a key ingredient in the company’s weight-loss and diabetes drugs, including top-seller Mounjaro.The lawsuits against…
Continue Reading
Diet weight loss company Noom entered into an agreement with Eli Lilly’s LillyDirect pharmacy provider Gifthealth to help improve access to FDA-approved Zepbound (tirzepatide) single-dose vials for Noom’s members with an on-label prescription from…
Continue Reading
What You Should Know:
– Noom, a digital healthcare company focused on chronic disease prevention and empowering healthy living announced an agreement with Gifthealth, the LillyDirect® pharmacy provider of Eli Lilly and Company.
– The collaboration…
Continue Reading
What You Should Know:
– Teladoc Health, the global leader in virtual care announced a partnership with Gifthealth, a digital pharmacy platform and partner of Eli Lilly’s LillyDirect program, to improve access to tirzepatide (brand…
Continue Reading
Understanding the Eye Risk Concerns
Recent findings have raised alarming concerns about potential ophthalmic complications associated with popular diabetes medications semaglutide and tirzepatide. These incretin-based therapies, while highly effective for managing type 2 diabetes and…
What You Should Know:
– Helix, a leader in population genomics and precision health, today announced the launch of a new clinico-genomic dataset comprising over 15,000 patients treated with glucagon-like peptide-1 (GLP-1) agonists.
– These medications,…
Continue Reading
A self-referral service has gone live across North East and North Cumbria Integrated Care System (ICS) to help NHS organisations manage growing demand for weight loss medications.
The online system, provided by digital health company…
